Sinocare Inc
SZSE:300298

Watchlist Manager
Sinocare Inc Logo
Sinocare Inc
SZSE:300298
Watchlist
Price: 25.71 CNY -0.43% Market Closed
Market Cap: 14.5B CNY
Have any thoughts about
Sinocare Inc?
Write Note
Sinocare Inc
/
Balance Sheet
/
Current Portion of Long-Term Debt

Sinocare Inc
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sinocare Inc
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Sinocare Inc
SZSE:300298
Current Portion of Long-Term Debt
¥393.1m
CAGR 3-Years
176%
CAGR 5-Years
150%
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Current Portion of Long-Term Debt
¥11.3m
CAGR 3-Years
31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Current Portion of Long-Term Debt
¥223.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Current Portion of Long-Term Debt
¥110.1m
CAGR 3-Years
13%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
J
Jafron Biomedical Co Ltd
SZSE:300529
Current Portion of Long-Term Debt
¥101.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Current Portion of Long-Term Debt
¥28.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Sinocare Inc
Glance View

Market Cap
14.2B CNY
Industry
Health Care

Nestled in the heart of China's burgeoning biotech industry, Sinocare Inc. has steadily transformed itself into a powerhouse in the realm of glucose monitoring and diabetes management. Founded in 2002, the company was driven by an urgent need to address the growing epidemic of diabetes in China and beyond. As diabetes continued to exact a heavy toll both economically and medically, Sinocare sought to leverage advanced technological innovations to pioneer user-friendly and affordable monitoring solutions. By placing a firm emphasis on research and development, the company sharpened its expertise in biosensing technology, allowing it to produce a comprehensive range of glucose monitors, test strips, and related healthcare products that cater not just to hospitals but also empower individuals with diabetes to manage their conditions effectively. In its journey, Sinocare smartly diversified beyond simple diagnostics into broader health management solutions. With an eye on increasing the accessibility and functionality of their products, they pursued strategic alliances and acquisitions, notably acquiring Nipro diagnostic business (now Trividia Health) and PTS Diagnostics. These moves helped broaden Sinocare’s horizons to international markets, offering it a stronger footing in the lucrative U.S. and European markets in addition to its dominant Asian presence. Sinocare makes money through the sale of its monitoring devices and the recurring revenue stream generated by test strips and other consumables. Their integrated approach, combining product sales with digital health management services, helps in building a robust ecosystem around its core offerings. This innovative business model not only boosts their bottom line but positions Sinocare as a critical player in the global fight against diabetes, continuously driving towards a future where chronic disease management is much more convenient and effective.

Intrinsic Value
35.83 CNY
Undervaluation 28%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Sinocare Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
393.1m CNY

Based on the financial report for Sep 30, 2024, Sinocare Inc's Current Portion of Long-Term Debt amounts to 393.1m CNY.

What is Sinocare Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
150%

Over the last year, the Current Portion of Long-Term Debt growth was 338%. The average annual Current Portion of Long-Term Debt growth rates for Sinocare Inc have been 176% over the past three years , 150% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 211,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.